期刊文献+

重组人促红细胞生成素治疗肾性贫血护理干预效果的观察 被引量:1

Observation of the effect of nursing intervention of the recombinant human erythropoietin on renal anemia in chronic renal failure patients
下载PDF
导出
摘要 目的:观察重组人促红细胞生成素治疗肾性贫血护理干预的效果。方法:36例患者随机分为实验组和对照组各18例。对照组给予常规护理、rHuEPO等药物治疗,实验组在此基础上予以护理干预,即心理护理、治疗护理、生活指导等,对两组的住院天数、红细胞数、血红蛋白、血细胞压积、不良反应作比较。结果:两组的血红蛋白、血细胞压积及不良反应差异有统计学意义(P<0.05)。结论:针对慢性肾衰竭贫血患者的特点,可从心理、治疗不良反应、饮食,不同注射方式、部位等方面进行护理干预,提高重组人促红细胞生成素的治疗效果。 Objective: To explore the clinical influence of nursing intervention on the curative effect of the recombinant human erythropoietin on renal anemia in chronic renal failure patients. Methods: Thirty six patients with renal anemia of chronic renal failure patients were randomly divided into experiment group (n = 18) and eontrol group (n = 18). Conventional nursing care and medication were given in control group and nursing intervention that strengthening psychological care, life care, diet instruction was given based on routine nursing care in experiment grnup.Results: Two groups of hemoglobin, blood cells, hematoerit and adverse reactions were statistically significant differences ( P 〈 0.05) .Conclusion: Nursing intervention can significantly increase the recombinant human erythropoietin in the treatment of the therapeutic effect.
出处 《中国民康医学》 2010年第4期420-421,436,共3页 Medical Journal of Chinese People’s Health
关键词 重组人促红细胞生成素 慢性肾脏病 肾性贫血 护理干预 Recombinant human erythropoietin Chronic kidney disease Renal anemia Nursing intervention
  • 相关文献

参考文献7

  • 1李香玲,肖青,刘江月,马传香,王敏,郭振涛.大剂量rHuEPO对肾性贫血患者骨髓红系及其超微结构的影响[J].山东医药,2007,47(25):28-29. 被引量:2
  • 2National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification [J]. Am J Kid Dis, 2002,39(Suppl 1) : 1 - 266.
  • 3俞雨生.如何合理治疗肾性贫血[J].肾脏病与透析肾移植杂志,2005,14(1):82-85. 被引量:17
  • 4Bamgboa OF, Kaskel F J, Coco M,et al. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts [ J]. Pediatr Nephrol, 2009,24 ( 3 ) : 571 - 579.
  • 5M ishel M H. Uncertainty in illness[ J]. Journal of Nursing Scholarship, 1988,20(4) :225 - 231.
  • 6Galloway SC, Graydon JE. Uncertainty symptom distress and infor2mation needs after surgeryfor cancer of the colon [ J]. Cancer Nursing, 1996, 19(2) : 112 - 117.
  • 7Neville, Kathleen L. Uncertainty in illness: An integrative review [ J]. National Association of Orthopaedic Nurses, 2003,22(3) : 206 -214.

二级参考文献16

  • 1Lawrence P McMahon. Advances in anaemia management: Current evidence. Nephrology,2002,7 (5) :257.
  • 2Jelkmann W. Molecular biology of erythropoietin. Int Med, 2004,43(8) :649.
  • 3National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease 2000. Am J Kidney Dis,2001,37:S182.
  • 4Macdougall IC. Optimizing erythropoietin therapy. Curr Opin Hematol, 1999,6:121.
  • 5Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron, 1996,72:413.
  • 6Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant, 1995,10:2070.
  • 7Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron, 1996,72: 413.
  • 8Taylor JE, Peat N, Porter C,et al. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant, 1996,11: 319.
  • 9Kosch M, Bahner U, Bettger H,et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose ( VenoferR ) vs iron gluconate (FerrlecitR ) in haemodialysis patients treated with rHuEPO. Nephrol Dial Transplant,2001,16: 1239.
  • 10Besarab A, Amin N, Ahsan M ,et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol,2000,11: 53.

共引文献17

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部